Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBI Brickell Biotech		$0.86	$2.21 ▼ $37.35	$6.75M	0.02	206,730 shs	31,300 shs
CRIS Curis	$2.45 -11.6%	$1.94	$1.02 ▼ $8.48	$25.63M	3.69	73,740 shs	70,277 shs
CYTH Cyclo Therapeutics	$0.72	$0.72	$0.55 ▼ $1.45	$23.72M	-0.57	514,360 shs	N/A
ELEV Elevation Oncology	$0.38 +0.4%	$0.33	$0.22 ▼ $3.28	$22.61M	1.43	1.51 million shs	801,319 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBI Brickell Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
CRIS Curis	0.00%	+3.38%	+22.50%	-13.73%	-72.16%
CYTH Cyclo Therapeutics	0.00%	0.00%	0.00%	+2.94%	-42.81%
ELEV Elevation Oncology	0.00%	+19.32%	+27.32%	-28.36%	-88.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBI Brickell Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRIS Curis	2.7884 of 5 stars	3.5	3.0	0.0	0.0	3.4	0.0	1.3
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	3.5159 of 5 stars	4.0	5.0	0.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBI Brickell Biotech	0.00	N/A	N/A	N/A
CRIS Curis	3.00	Buy	$17.00	593.88% Upside
CYTH Cyclo Therapeutics	2.33	Hold	$0.95	31.83% Upside
ELEV Elevation Oncology	2.00	Hold	$3.39	787.01% Upside

Current Analyst Ratings Breakdown

Latest BBI, CRIS, CYTH, and ELEV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	ELEV Elevation Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/10/2025	ELEV Elevation Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral
6/9/2025	ELEV Elevation Oncology	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/9/2025	ELEV Elevation Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
3/31/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $16.00
3/24/2025	ELEV Elevation Oncology	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$5.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
3/21/2025	ELEV Elevation Oncology	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$9.00 ➝ $1.00
3/21/2025	ELEV Elevation Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/21/2025	ELEV Elevation Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$10.00 ➝ $0.70

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBI Brickell Biotech	$4.64M	0.00	N/A	N/A	$9.75 per share	0.00
CRIS Curis	$11.20M	2.29	N/A	N/A	$3.34 per share	0.73
CYTH Cyclo Therapeutics	$870.73K	27.24	N/A	N/A	$0.21 per share	3.43
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBI Brickell Biotech	-$39.47M	-$13.52	N/A	N/A	N/A	-643.48%	-156.10%	-128.23%	N/A
CRIS Curis	-$47.41M	-$6.23	N/A	N/A	N/A	-443.35%	-923.37%	-78.35%	7/30/2025 (Estimated)
CYTH Cyclo Therapeutics	-$20.06M	-$0.90	N/A	N/A	N/A	-2,847.19%	N/A	-307.16%	N/A
ELEV Elevation Oncology	-$45.70M	-$0.82	N/A	N/A	N/A	N/A	-59.73%	-40.05%	8/5/2025 (Estimated)

Latest BBI, CRIS, CYTH, and ELEV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ELEV Elevation Oncology	-$0.20	-$0.24	-$0.04	-$0.24	N/A	N/A
5/6/2025	Q1 2025	CRIS Curis	-$1.14	-$1.25	-$0.11	-$1.25	$2.37 million	$2.38 million
3/31/2025	Q4 2024	CRIS Curis	-$1.36	-$1.25	+$0.11	-$1.25	$2.04 million	$2.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBI Brickell Biotech	N/A	N/A	N/A	N/A	N/A
CRIS Curis	N/A	N/A	N/A	N/A	N/A
CYTH Cyclo Therapeutics	N/A	N/A	N/A	N/A	N/A
ELEV Elevation Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBI Brickell Biotech	N/A	6.36	6.36
CRIS Curis	N/A	1.22	1.22
CYTH Cyclo Therapeutics	N/A	0.17	0.16
ELEV Elevation Oncology	0.45	17.77	17.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBI Brickell Biotech	N/A
CRIS Curis	29.97%
CYTH Cyclo Therapeutics	68.55%
ELEV Elevation Oncology	83.70%

Insider Ownership

Company	Insider Ownership
BBI Brickell Biotech	4.53%
CRIS Curis	5.70%
CYTH Cyclo Therapeutics	29.78%
ELEV Elevation Oncology	8.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBI Brickell Biotech	16	2.87 million	2.74 million	Not Optionable
CRIS Curis	60	10.46 million	7.98 million	No Data
CYTH Cyclo Therapeutics	9	32.92 million	23.12 million	No Data
ELEV Elevation Oncology	40	59.22 million	54.33 million	Optionable

BBI, CRIS, CYTH, and ELEV Headlines

Recent News About These Companies

HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)

June 15 at 1:27 PM | globenewswire.com

HC Wainwright Has Strong Estimate for ELEV FY2025 Earnings

June 14 at 2:35 AM | americanbankingnews.com

Q2 EPS Estimate for Elevation Oncology Decreased by Analyst

June 14 at 1:31 AM | americanbankingnews.com

What is HC Wainwright's Estimate for ELEV Q3 Earnings?

June 13 at 3:41 AM | americanbankingnews.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KNW, ELEV, CRKN on Behalf of Shareholders

June 12 at 1:57 PM | prnewswire.com

Elevation Oncology (NASDAQ:ELEV) Receives "Market Perform" Rating from JMP Securities

June 12 at 2:56 AM | americanbankingnews.com

Q2 EPS Estimates for Elevation Oncology Reduced by Wedbush

June 12 at 1:53 AM | americanbankingnews.com

Elevation Oncology (NASDAQ:ELEV) Downgraded to "Neutral" Rating by HC Wainwright

June 12 at 1:19 AM | americanbankingnews.com

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation ...

June 12 at 1:18 AM | morningstar.com

HC Wainwright & Co. Downgrades Elevation Oncology (ELEV)

June 12 at 1:18 AM | msn.com

Concentra buys out another struggling Boston biotech

June 11, 2025 | bizjournals.com

William Blair Reaffirms "Market Perform" Rating for Elevation Oncology (NASDAQ:ELEV)

June 11, 2025 | americanbankingnews.com

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

June 10, 2025 | businesswire.com

Elevation Oncology agrees to be acquired by Concentra

June 10, 2025 | thepharmaletter.com

Elevation Oncology stock soars on Concentra merger agreement

June 10, 2025 | au.investing.com

Concentra Biosciences to Buy Out Elevation Oncology After Pipeline Reshuffle

June 10, 2025 | precisionmedicineonline.com

Elevation Oncology to Be Acquired by Concentra Biosciences

June 10, 2025 | marketwatch.com

Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’

June 10, 2025 | finance.yahoo.com

Embattled Elevation becomes latest biotech to accept Concentra buyout offer

June 10, 2025 | fiercebiotech.com

ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. ...

June 9, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBI, CRIS, CYTH, and ELEV Company Descriptions

Brickell Biotech NASDAQ:BBI

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Curis NASDAQ:CRIS

$2.45 -0.32 (-11.55%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.57 +0.12 (+4.90%)

As of 06/13/2025 07:40 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Cyclo Therapeutics NASDAQ:CYTH

$0.72 0.00 (0.00%)

As of 03/26/2025

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Elevation Oncology NASDAQ:ELEV

$0.38 +0.00 (+0.39%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.38 +0.00 (+0.08%)

As of 06/13/2025 07:41 PM Eastern

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time